Recruiting · registry statusStudying swallowing and voice-box function
Researchers record routine throat examination findings and swallowing difficulties in people with conditions affecting the brain and nervous system.
Learning by observing or collecting information · Study reference: NCT04706234
Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓
This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.
Open the official registry record ↗Follow this study
Looking for volunteers
- Start (reported actual date)
- 2017-09-01
- Main measurements finished (planned)
- 2027-12-31
- Study finished (planned)
- 2028-07-31
Planned dates can move. A study finishing does not tell us when a paper will be published.
No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.
Changes we have recorded
These are dates we observed a change, not necessarily the dates it happened.
Papers connected to this study
No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.
Who can join?
Age 18 years and over · Does not accept healthy volunteers
These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.
Read all the rules for taking part
Sex eligibility reported by registry: all
Inclusion Criteria:
* diagnosis of probable or possible multiple system atrophy according to current consensus criteria (Gilman et al. 2008) or
* diagnosis of probable or possible PSP according to the the Movement Disorders Society (MDS) diagnostic criteria (Höglinger et al. 2017) or
* diagnosis of Parkinson's disease according to the MDS diagnostic criteria (Postuma et al 2015)
* Hoehn and Yahr Stage within the range of I-V or
* diagnosis of motor neurone disease or
* diagnosis of a neurodegenerative disease other than specified above
AND underwent laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
Exclusion Criteria:
\- Patients who do not sign the consent form
Full study name & original research details
Official study title
Prospective Observational Study for the Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases
Short title used by the registry
Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases
Original description
This is a non-interventional observational study designed to systematically record the results of routine laryngeal examinations and specific characteristics of dysphagia in patients with neurodegenerative disorders. The results of a fiberoptic / flexible endoscopic evaluation of swallowing (FEES) while performing a structured task protocol will be recorded. If available, laryngeal electromyography (EMG) results will also be recorded. In addition to the examination results, demographic and disease-specific data are collected, and two questionnaires, the Swallowing Disturbance Questionnaire for Parkinson's Disease (SDQ-PD) and the swallowing specific Quality Of Life Questionnaire (SWALQOL), are administered.
Further description from the registry
Neurodegenerative disorders are associated with a high prevalence of neurogenic dysphagia. Depending on the underlying disease, the prevalence can affect up to 80% of patients. Dysphagia is associated with dehydration, malnutrition, facilitates aspiration pneumonia and thereby determines the prognosis of neurodegenerative diseases. For most of them, dysphagia-associated complications are the leading cause of death.
Multiple system atrophy (MSA) is a sporadic progressive neurodegenerative disorder caused by oligodendroglial aggregation of α-synuclein affecting predominantly the nigrostriatal, olivo-ponto-cerebellar, and autonomic systems,resulting in a clinical presentation of dysautonomia combined with either predominantly parkinsonian (MSA-P) or cerebellar (MSA-C) symptoms of varying severity.In its early stage, the diagnosis of MSA according to the second consensus criteria can be challenging. Therefore, the Movement Disorders Society MSA study group recently addressed the importance of developing valuable diagnostic tools for securing an early diagnosis in patients with MSA not only to estimate disease prognosis but also to early initiate novel, potentially disease-modifying treatments in clinical trials. Despite laryngopharyngeal dysfunction being associated with decreased life expectancy and quality of life, systematic assessment of these functions in MSA is scarce. Previously, an easy-to-implement MSA-FEES task-protocol was suggested to systematically assess laryngopharyngeal function.
A pilot study on 8 patients with MSA not only showed that the task protocol was feasible and well tolerated, but also that laryngopharyngeal symptoms where highly prevalent despite the lack of clinical presentation (Warnecke et. al 2019). Moreover, irregular arytenoid cartilages movements where present in all MSA-patients when performing this task protocol, suggesting this symptom could serve as a clinical marker to identify MSA-patients. Following this pilot study, an observational two center study assessed 57 MSA patients with this protocol and compared findings to an age-matched cohort of PD-patients (Gandor et al. 2020). While only 43.9% of MSA patients had clinical symptoms of laryngeal dysfunction, 93% showed laryngeal abnormalities during FEES performing the task-protocol. 91.2% of MSA-patients showed irregular arytenoid cartilages movements. In contrast, only one PD patient showed laryngeal abnormalities with vocal fold motion impairment, but not irregular arytenoid cartilages movements. This study suggests that irregular arytenoid cartilages movements allow differentiating MSA from PD with a sensitivity of 0.9 and a specificity of 1.0.
4repeat tauopathies (4RT) are caused by an intraneuronal accumulation of 4repeat tau.
4RT, also known as progressive supranuclear palsy (PSP) with all its clinical subtypes, is a rapidly progressive neurodegenerative disease that leads to increasing impairment of cortical and subcortical function in the affected person due to the accumulation of tau protein in the brain (Höglinger 2017). Due to the clinical variability of the presentation, early diagnostic certainty is desirable. Depending on the affected area in the central nervous system, different clinical phenotypes result. The most commonly described and researched entity is Progressive Supranuclear P, also known as Richardson Syndrome, or PSP-RS. Further clinical presentations include a Parkinsonian variant (PSP-P), corticobasal syndrome (PSP-CBS), pure akinesia with gait freezing (PSP-PAGF), speech/language dominant presentations (PSP-SL), frontotemproal dementia variants (PSP-FTD), and cerebellar presentations (PSP-C) (Höglinger 2017).
4RT is also associated with swallowing and speech problems, and aspiration pneumonia is one of the most common causes of death in this disease entity (Tilley 2016). In addition, dystonic dysinnervation of laryngeal muscles can lead to laryngeal motion abnormalities (Panegyres 2007).
Equally, patients with motor neurone disease (MND) are affected by dysphagia early in the disease. In a FEES study by Steven B. Leder and colleagues (2004), which included 17 ALS patients subjectively complaining of dysphagia, fluid aspiration or an increased risk of fluid aspiration was found in almost 60% of cases, regardless of whether the disease initially mainly affected the bulbar musculature or the limb musculature. As the disease progressed, the depth of penetration of fluids into the hypopharynx prior to triggering the swallowing reflex increased, so these patients were advised to thicken fluids. Initially, residues of solid food consistencies were detected in the valleculae, piriform sinus and/or laryngeal inlet in three patients after swallowing. As a result of progressive paresis of the pharyngeal muscles, the residuals increased in the ALS patients examined during the course of the disease. If this disorder pattern was detected, it was advised to reduce the size of the food bolus and to clear the pharynx by swallowing water or reswallowing several times. In a further small case series (n = 11), the FEES showed that dysphagic ALS patients are particularly at risk of penetration/aspiration when swallowing liquids. Penetration and aspiration occur particularly frequently intradeglutitively (D'Ottaviano et al. 2013). A recent publication reports on FEES examinations in 202 ALS patients (w/m 95/107; bulbar/spinal onset 66/136; mean age 64.68 +/- 11.12 years). A close positive correlation with disease severity (measured using the ALSFRS-R) was found for all FEES parameters (leaking, aspiration, residuals), regardless of the three consistencies tested (liquid, semi-solid, solid) (Fattori et al. 2017).
The aim of this FEEMSA trial is to continue recruitment of patients with neurodegenerative diseases and systematically assess laryngopharyngeal function in large cohorts, to categorise the dysphagia phenotypes and better correlate them with the disease subtypes (MSA Parkinson vs cerebellar; PSP variants, MND variants, etc). If available, laryngeal EMG will also be recorded.
Conditions reported: Multiple System Atrophy; Parkinson Disease; Progressive Supranuclear Palsy; Motor Neuron Disease; Neurodegenerative Diseases
Registry records for this study
Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.
- Study type
- Observational
- Interventions
- Not reported
- Phases
- Not reported
- Sponsor
- Kliniken Beelitz GmbH
- Start date reported by registry
- 2017-09-01 (actual)
Registry updated: 2025-04-09 · Status last verified by the registry submitter: 2025-04
Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.
Contact the research team
Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.
Florin Gandor, MD · +493320422781 · gandor@kliniken-beelitz.de
Tobias Warnecke, MD · tobias.warnecke@klinikum-os.de
Study locations
Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.
Department of Neurology and Department of ENT, Medical University Innsbruck
Innsbruck, Tyrol, Austria
RecruitingGregor Wenning, MD, PhD, MSc · +43676596 · gregor.wenning@i-med.ac.at
Alessandra Fanciulli, MD, PhD · +435125048 · Alessandra.Fanciulli@i-med.ac.at
Klaus Seppi, MD, PhD
Claus Pototschnig, MD, MSc
Florian Krismer, MD
Oliver Galvan, MD
Fabian Leys, MD
Cecilia Raccagni, MD
Victoria Sideroff, MD
Roberta Granata, MD
Department of Neurology, Medical University of Ulm
Ulm, Baden-Wurttemberg, Germany
RecruitingJan Kassubek, MD · jan.kassubek@uni-ulm.de
Rebecca Kassubek, MD · rebecca.kassubek@uni-ulm.de
Beate Lindner-Pfleghar, M.Sc.
Movement Disorders Hospital - Kliniken Beelitz
Beelitz-Heilstätten, Brandenburg, Germany
RecruitingFlorin Gandor, MD · +49332042 · gandor@kliniken-beelitz.de
Doreen Gruber, MD · +49332042 · gruber@kliniken-beelitz.de
Annemarie Vogel, M.Sc.
Georg Ebersbach, MD
Department of Neurology, Medical School Hannover
Hanover, Lower Saxony, Germany
RecruitingMartin Klietz, MD · martin.klietz@mh-hannover.de
Katharina Pannewitz-Makaj, MD · Pannewitz-Makaj.Katharina@mh-hannover.de
Christoph Schrader, MD
Department of Neurology, University Hospital Münster
Münster, North Rhine-Westphalia, Germany
RecruitingInga Claus, MD · inga.claus@ukmuenster.de
Sigrid Ahring
Department of Neurology, University Hospital Carl Gustav Carus
Dresden, Saxony, Germany
RecruitingBjörn Falkenburger, MD · +49351458 · Bjoern.Falkenburger@dzne.de
Inaki Schniewind, MD · Inaki.Schniewind@uniklinikum-dresden.de
Department of Neueology Asklepios Klinik Stadtroda
Stadtroda, Thuringia, Germany
RecruitingDavid Weise · +49 36428 56 · mailto:da.weise@asklepios.com
Asklepios Fachklinikum Stadtroda
Stadtroda, Thuringia, Germany
RecruitingDavid Weise, PD Dr · da.weise@asklepios.com
Asklepios Klinik Barmbek
Hamburg, Germany
RecruitingPeter P Urban, Prof. · c.herborn@asklepios.com
Department of Neurology Asklepios Klinik Barmbek
Hamburg, Germany
RecruitingPeter Urban, MD · 0401818823841 · p.urban@asklepios.com
Department of Neurology, Movement Disorders Unit, Medical Center Tel Aviv
Tel Aviv, Israel
RecruitingTanya Gurevich, MD · tanyag@tlvmc.gov.il
Adi Ezra · adil@tlvmc.gov.il
IRCCS Istituto delle Scienze Neurologiche, Azienda USL di Bologna
Bologna, Italy
RecruitingGiulia Giannini, MD, PhD · giulia.giannini15@unibo.it
Luca Baldelli, MD · luca.baldelli4@unibo.it
Department of Neurology, Gifu University Graduate School of Medicine
Gifu, Japan
RecruitingTakayoshi Shimohata, MD PhD
Kenjiro Kunieda, MD PhD · +81 58 230 6254 · ken2rou.k@gmail.com
Department of Neurology, Medical University Warsaw
Warsaw, Poland
RecruitingAndrzej Friedman, MD, PhD · andrzej.friedman@wum.edu.pl
Natalia Madetko, MD · natalia.madetko@wum.edu.pl
Department of Neurology SNUCM
Seoul, South Korea
RecruitingKim Han-Joon, MD PhD · movement@snu.ac.kr
Unidad de Parkinson y Trastornos del Movimiento Instituto Clínic de Neurociencias, Hospital Clinic de Barcelona
Barcelona, Catalonia, Spain
RecruitingMaria J Marti, MD PhD · +34 93 227 57 85 · mjmarti@clinic.cat
Alexandra Perez, MD · +34 93 227 57 85 · aperez3@clinic.cat
Isabel Vilaseca, MD
Facility not reported
Austria
Status not reportedFacility not reported
Germany
Status not reportedFacility not reported
Israel
Status not reportedFacility not reported
Italy
Status not reportedFacility not reported
Japan
Status not reportedFacility not reported
Korea, Republic of
Status not reportedFacility not reported
Poland
Status not reportedFacility not reported
Spain
Status not reportedThe original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.